UPDATE: Instil Bio Q2 Adj $(0.11) Beats $(0.16) Estimate
Portfolio Pulse from Happy Mohamed
Instil Bio (NASDAQ:TIL) reported Q2 losses of $(0.11) per share, beating the analyst consensus estimate of $(0.16) by 31.25%. This represents a 76.09% increase over losses of $(0.46) per share from the same period last year.
August 14, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Instil Bio's Q2 earnings beat analyst estimates by 31.25%, indicating a better-than-expected financial performance. This could potentially lead to a positive short-term impact on the stock.
Instil Bio's Q2 earnings beat analyst estimates, which is generally seen as a positive sign by investors. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100